Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of ...

Upon approval, Rocket has been awarded a priority review voucher, which currently fetch around $200m on the secondary market.

With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit.  | Rocket ...

The California Institute for Regenerative Medicine (CIRM) celebrates a major milestone in the agency’s 21-year history: the first approved therapy to come out of California taxpayer funding. The U.S.

Marne-cel now offers an option to children with the rare immune disorder who lack a sibling donor for stem cell ...

The U.S. Food and Drug Administration has approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant therapy to treat patients with severe aplastic anemia (SAA). Omisirge is ...

It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...

The U.S. FDA’s green lighting of Omeros Corp.’s Yartemlea (narsoplimab) makes it the first approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...

Add Yahoo as a preferred source to see more of our stories on Google. Under Health and Human Services Secretary Robert F. Kennedy Jr., will the Food and Drug Administration still rein in bogus claims ...

Dec. 8 (UPI) --The U.S. Food and Drug Administration on Monday announced the approval of the first hematopoietic stem cell transplant therapy to treat patients with rare but severe aplastic anemia.

I'll say this for the promoters of bogus stem cell treatments: They are terrific at finding new ways to market their goods and services. For example, we've seen the proliferation of clinics offering ...